GSK’s Quad Flu Vaccine Clears FDA; B-Strain Protection Gap Could Drive Adoption
This article was originally published in The Pink Sheet Daily
Executive Summary
About one-third of the influenza B viruses tested this year are from the strain not included in this season’s trivalent vaccine; GlaxoSmithKline’s Fluarix is the second approved seasonal flu vaccine to protect against four virus strains, and by next season half of the U.S. manufacturers could be offering a broader spectrum product.
You may also be interested in...
Quadrivalent FluMist Clears FDA But Won’t Be On The Market Until 2013
MedImmune does not expect improved sales of the intranasal vaccine based on the enhanced formulation.
Social Media Data Gains Prominence In Patient-Focused Drug Development
FDA guidances have provided ‘major step forward’ for use of social media data, Roche researcher notes. Agency staffer offers checklist for collecting patient experience data in this realm.
Missing Data Hinders Inclusion Of Patient Experience In Drug Labeling, US FDA Says
Agency staff note hurdles in obtaining evidence outlined in FDA’s patient-focused drug development guidance to support regulatory decision-making.